Shweta Maniar’s Post

Just back from Fierce Biotech JPM Virtual Week, and my mind is buzzing with the future of biotech! From AI's revolutionary touch to cutting-edge cancer treatments, this event was a powerhouse of insights and connections. Key Takeaways: 1) AI is redefining drug discovery and clinical trials: Experts like Johanna Mercier (Gilead Sciences) and Juergen Eckhardt (Bayer) highlighted the immense potential of AI to accelerate innovation and improve patient outcomes. 🖥 2) Oncology's next frontier is exhilarating: Discussions on ADCs, Radio-pharma, and cell & gene therapies showcased the promise of personalized, targeted cancer treatments. 3) Biopharma leaders like Marianne D. De Backer, MSc, PhD, MBA (Vir Biotechnology, Inc.) and Andrew Obenshain (bluebird bio) shared inspiring journeys and valuable insights on navigating market challenges and building successful startups. 🏢 4) Fierce conversations on topics like the Inflation Reduction Act and pharmacy benefit managers sparked thoughtful debates about the future of healthcare policy. ⚖️ This was just a glimpse into the wealth of knowledge and connections I gained at Fierce JPM Week. Much more to come 🔥 !! #FierceJPMWeek #biotech #AI #Healthcare #Innovation #Leadership #biopharma #cancerresearch

Great minds think alike. And sometimes, they work together 😉 We’re excited to share some of our recent partnerships to innovation: - Receiving funding support of up to $125 million from Royalty Pharma to advance treatments for schizophrenia - Collaborating with Sanofi to develop new therapies for patients with inflammatory bowel disease - Working with Alvotech to develop biosimilar treatments for rheumatoid arthritis and other chronic conditions - Exploring computational biology and AI with Biolojic Design to create new therapies for dermatitis and asthma - Co-founding AION Labs with industry leaders to use AI and big data to speed up the discovery of new drugs - Building over 30 collaborations with research institutions to work with leading labs around the world - Conducting early biomarker research with MetaSight Diagnostics to develop liquid biopsy diagnostics for the early detection of chronic and acute diseases We’re proud to be part of the strategic partnerships for scientific breakthroughs. More here > https://ow.ly/2kRf50TPf7h #Tevapharm #TevaCareers #WeAreAllInForBetterHealth #PivotToGrowth

🚲 Where will you be on 12th & 13th November 2024? 🚲 AMSTERDAM! This year's #COGEurope takes place in the bicycle capital of the world, convening at the Novotel Amsterdam City. A snapshot of the conference agenda in 3 key themes: Patient-Centricity and Engagement Emphasising putting patients at the heart of clinical trials, sessions focused on enhancing patient-centricity, diversity, and engagement. There are discussions on #patientrecruitment and retention strategies, improving patient exposure to healthcare, and integrating patient perspectives into the wider research process. Clinical Trial Efficiency and Innovation Addressing ways to optimise and innovate #clinicaltrial processes. Including topics like maximizing trial efficiency, utilising #artificialintelligence in clinical operations, adopting #digitalhealth technologies, and implementing quality by design principles. There's also a focus on navigating challenges in specific areas like gene therapy trials and obesity studies. Funding and Strategic Partnerships Covering various aspects of funding and partnerships in clinical research. This includes sessions on securing investment for clinical-stage #biopharma companies, strategies for attracting funding, and building effective partnerships between trial sponsors and investigators. There are also discussions on vendor selection, #outsourcing, and supply chain management in clinical trials. These themes reflect COG Europe's focus on improving clinical trial processes, enhancing patient involvement, and addressing the business and partnership aspects of #clinicalresearch. Bought to you by PBC Group - Organisers of the COG Series

𝐔𝐧𝐯𝐞𝐢𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐨𝐟 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲: 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐆𝐫𝐨𝐰𝐭𝐡 𝐓𝐫𝐞𝐧𝐝𝐬 The global #liquid_biopsy_market is poised for significant growth, with a projected CAGR of 26% by 2028. This surge is fueled by factors like rising cancer prevalence and the increasing adoption of minimally invasive diagnostic techniques. 𝐌𝐚𝐫𝐤𝐍𝐭𝐞𝐥 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐬' new "Liquid Biopsy Market" report provides a detailed analysis of this evolving landscape, offering valuable insights into: 🔷𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐚𝐧𝐝 𝐬𝐡𝐚𝐫𝐞: Gain a clear understanding of the market's current value and how it's expected to evolve. 🔷𝐆𝐫𝐨𝐰𝐭𝐡 𝐭𝐫𝐞𝐧𝐝𝐬: Identify key drivers and challenges shaping the market's future trajectory. 🔷𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: Analyze the leading players and their strategic approaches. Empower your decision-making with comprehensive market intelligence. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐲𝐨𝐮𝐫 𝐟𝐫𝐞𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐭𝐨𝐝𝐚𝐲: https://lnkd.in/gBNjkWBi 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬- Bio-Rad Laboratories, Biocept, Inc. , ABCODIA LIMITED, Epic Sciences, Roche, Guardant Health, Illumina, NeoGenomics Laboratories, Menarini Silicon Biosystems, and many more. #healthcare #healthcareindustry #health #liquidbiopsy #marketresearchreports #futureofdiagnostics #marketgrowth #marketanalysis #industryanalysis #industryinsights #marknteladvisors #consulting

Are you lost navigating the complex landscape of clinical development? Look no further!   WEP Clinical specializes in creating customized strategies to propel your clinical development program forward. Here’s how we can assist:   Clinical Development Planning Made Personal: · Our team of experts crafts tailored clinical development plans. · From adaptive designs to basket studies, we address your unique program needs. · Let us shorten your time to patient impact while ensuring robust planning. Target Product Profile (TPP) Creation: · Define the desired characteristics of your product. · Analyze your criteria, prepare for best-and worst-case scenarios, and catch the attention of funders and developers. Submission Strategy and Regulatory Support: · Navigate regulatory processes confidently. · We provide robust submission support for IND, NDA, MAA, and BLA filings. · Expedited programs? Breakthrough designations? We’ve got you covered. Global Reach and Expertise: · With years of experience, we operate across continents. · Our comprehensive capabilities include expertise in cell and gene therapy, rare disease, and oncology.   Join forces with WEP Clinical for innovative solutions that accelerate your clinical development journey!  Reach out to schedule a meeting to learn more about our services. #WEPClinical #PatientAccess #ClinicalDevelopment #ResearchPartnership #PatientImpact

Come Together: OncoDxRx’s PGA and OncoMRD Close the Gap of Precision Medicine to Benefit Non-Responders Among the key weapons deployed by cancer cells, the heterogeneity was, along with the drug resistance, the most worrying for the clinicians. This highly dynamic malignancy had, in fact, the potential to profoundly transform the geometry of cancer combat, by considerably reducing the reaction times of modern Dx and Rx, while being almost invulnerable to the targeted therapy and immunotherapy existing today. OncoDxRx’s aim is to strengthen our precision Dx capability. This will lead to “transformative technologies regarding specific solutions that will allow filling gaps, reducing costs and shortening implementation times”. PGA (patient-derived gene expression-informed anticancer drug efficacy) and OncoMRD (monitoring residual disease) technologies are equipped with numerous innovations that allow them to demonstrate differentiating capabilities in precision oncology areas. OncoDxRx’s one-of-a-kind tests are able to guide treatment selection and monitor drug efficacy while remaining cost- and time-efficiency thanks to the automated and streamline workflow. The integration of state-of-the-art mRNA biomarkers and data analytics also gives them superior predictive power and surveillance, detection and tracking capabilities. PGA and OncoMRD are exclusive and disruptive technologies. They bring unmatched high quality gene expression profiles derived directly from patients. Finally, these technologies come with digital computation that facilitate the delivery of customized reports in 5 days.   #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Flagship Pioneering's Mirai Bio is breaking new ground with an AI-powered, open platform that promises to solve some of biotech’s toughest challenges in genetic medicine—delivery, design, and manufacturing. For professionals in biotech, this means: 🔬 Access to machine learning-driven solutions for precision therapies. 🤝 A collaborative platform that can accelerate development, making it easier to bring genetic therapies to market. 📊 The ability to tap into vast datasets for continual optimization across multiple therapeutic areas like oncology, immunology, and more. Check out the full article for more details... ARCH Venture Partners Kristina Burow Kent Rogers Axel Bouchon Steve Gillis Hari Pujar Mirai Bio Jagesh Shah Ashley Porras Flagship Pioneering Geoffrey von Maltzahn Pheast Therapeutics Roy Maute Be Biopharma Krishnan Viswanadhan, Pharm.D #Biotech #GeneticMedicine #AI #Innovation #Biopharma #HealthcareTech

Out Now! Clinical Operations Spotlight - Edition 02

Hundreds of biotech startups are exploring how AI could transform their businesses. So are big players like Johnson and Johnson, Abbot Labs, Merck, GlaxoSmithKline, and dozens more. And why wouldn’t they? According to research firm McKinsey, with AI we’ll be able to find drugs in one-tenth the time. Processes that used to take months will be done in days. That means more lifesaving drugs hitting the market for all types of deadly diseases… Heart disease… Breast cancer… Skin disease… Blindness… Lung cancer… And many, many more. Think about heart disease alone… It’s the leading cause of death in America, killing around 700,000 people annually. AI can spot it early with 93% accuracy. By comparison, a mammogram is only 85% accurate. Yes… AI is better at detecting heart disease than a mammogram is at breast cancer. Obviously, this is going to be fantastic on a human level. But it could just as fantastic for investors. Already, drug companies are some of the best performers on the market. Eli Lilly’s drug pipeline has helped it average 243% per year – for the past 15 years. #AIrevolution #Healthcare

𝐈𝐦𝐦𝐞𝐫𝐬𝐞 𝐲𝐨𝐮𝐫𝐬𝐞𝐥𝐟 𝐢𝐧 𝐭𝐡𝐞 𝐡𝐞𝐚𝐫𝐭 𝐨𝐟 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐈𝐦𝐦𝐮𝐧𝐨 𝟐𝟎𝟐𝟑! 🚀 Day One, Track 3 unfolds a captivating journey through 'IO Clinical Trials: Design, Data-Management & Case Studies.' Join us for an enriching experience as Sylwia Marshall, Kieran Whelton, Jens Kringelum, Andrew Pierce, and Barbara Losch share their expertise. 📚 𝐓𝐡𝐢𝐬 𝐭𝐫𝐚𝐜𝐤 𝐰𝐢𝐥𝐥 𝐝𝐞𝐥𝐯𝐞 𝐢𝐧𝐭𝐨: 𝐏𝐚𝐫𝐭 𝟏 - Clinical Trial Design & Data Management ✔️ Implementation of successful trial design strategies & new trends in trial design ✔️ Patient-specific immunotherapy using adaptive clinical study designs ✔️ Leveraging digital technologies & AI/ML in IO therapy development ✔️ Using & managing IO datasets 𝐏𝐚𝐫𝐭 𝟐 - Clinical Development Case Studies ✔️ Protein aggregations and preventions ✔️ Case Studies of IO Therapeutics in Clinical Stages: Multi-specific Immunotherapies, Checkpoint Inhibitors, Cell Therapies ➡️📖 Secure your spot and explore further details: https://hubs.la/Q02gVFqW0 #OGImmuno #Immuno24 #ClinicalTrials #Immunotherapy